ConCallIQ
Go Pro
Home › Divi's Laboratories › PAT History

Divi's Laboratories PAT History — Quarter by Quarter

Divi's Laboratories's pat moved from ₹356 Cr in Q1 FY24 to ₹583 Cr in Q3 FY26, a 63.8% change over 10 quarters. The table keeps each quarter linked back to the underlying earnings page.

PAT by Quarter

QuarterPAT (₹ Cr)YoY Change
Q3 FY26₹583 Cr-1%
Q2 FY26₹689 Cr+35.1%
Q1 FY26₹545 Cr+26.74%
Q4 FY25₹662 Cr+23.05%
Q3 FY25₹589 Cr+64.5%
Q2 FY25₹510 Cr+46.55%
Q1 FY25₹430 Cr+20.79%
Q3 FY24₹358 Cr—
Q2 FY24₹348 Cr—
Q1 FY24₹356 Cr—

What management said about pat

G

Q3 FY26 · Double-digit revenue growth trajectory maintained

Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.

G

Q1 FY25 · New generic products to commercialize in FY26

Emerging generic products with DMF filings planned for completion in the next few months will be commercialized in FY2026, targeting patent expiries in 2025-27.

G

Q1 FY24 · Double-digit revenue growth over medium term

Management anticipates double-digit revenue growth going forward, driven by custom synthesis, contrast media, and Sartans.